Finally, it has been speculated that the magnitude of BP reduction afforded by SGLT-2 inhibitors appears similar to that seen with other recently FDA-approved treatments for patients with hypertension, such as aprocitentan [48] and renal denervation [73]. The gene discussed is SLC5A2; the disease is hypertensive disorder.